News >

TAS-102 Nears EU Approval for Gastric Cancer

Jason M. Broderick @jasoncology
Published: Friday, Jul 26, 2019

Josep Tabernero, MD, PhD

Josep Tabernero, MD, PhD
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has backed approval of TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of adult patients with metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction (GEJ), following treatment with at least 2 prior systemic regimens for advanced disease.

TAS-102 was previously approved in the EU for the treatment of patients with colorectal cancer (CRC). In the United States, TAS-102 has approved indications for CRC and gastric/GEJ cancer.
Arkenau H-T, Tabernero J, Shitara K, et al. TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Presented at: 2018 ESMO Congress; October 19-23, 2018; Munich, Germany. LBA25.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Consultations®: Discussing the Nurse's Role in Treating and Managing Advanced Pancreatic AdenocarcinomaSep 28, 20191.5
Publication Bottom Border
Border Publication
x